N-[4-chloro-3-(trifluoromethyl)phenyl]-3-(3-hydroxyphenyl)propanamide | 900254-49-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-chloro-3-(trifluoromethyl)phenyl]-3-(3-hydroxyphenyl)propanamide
• CAS: 900254-49-1
• 化学式: C₁₆H₁₃ClF₃NO₂
• 分子量: 343.733
• InChiKey: HKHPLNHIFVDSSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,4-二氯嘧啶 、 N-[4-chloro-3-(trifluoromethyl)phenyl]-3-(3-hydroxyphenyl)propanamide 在 N,N-二甲基甲酰胺 caesium carbonate 作用下， 以 四氢呋喃 为溶剂， 以77%的产率得到3-{3-[(2-chloropyrimidin-4-yl)oxy]phenyl}-N-[4-chloro-3-(trifluoromethyl)phenyl]propanamide
  参考文献：
  名称：

  Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity

  摘要：

  本发明提供了一种新型的肉桂酰胺化合物，可用作蛋白激酶的抑制剂。该发明还提供了包括该发明化合物的药物组合物，以及在治疗各种疾病中使用这些组合物的方法。

  公开号：

  US20060160803A1
• 作为产物：
  描述：

  3-(3-羟基苯基)丙酸 、 2-氯-5-氨基三氟甲苯 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 0.25h， 生成 N-[4-chloro-3-(trifluoromethyl)phenyl]-3-(3-hydroxyphenyl)propanamide
  参考文献：
  名称：

  Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors

  摘要：

  Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

  DOI：

  10.1021/jm101479y

文献信息

• CINNAMIDE AND HYDROCINNAMIDE DERIVATIVES WITH RAF-KINASE INHIBITORY ACTIVITY
  申请人：MILLENNIUM PHARMACEUTICALS, INC.

  公开号：EP1856053A1

  公开（公告）日：2007-11-21
• US7652041B2
  申请人：——

  公开号：US7652041B2

  公开（公告）日：2010-01-26
• [EN] CINNAMIDE AND HYDROCINNAMIDE DERIVATIVES WITH RAF-KINASE INHIBITORY ACTIVITY<br/>[FR] DERIVES DE CINNAMIDE ET D'HYDROCINNAMIDE PRESENTANT UNE ACTIVITE INHIBITRICE DE RAF-KINASE
  申请人：MILLENNIUM PHARM INC

  公开号：WO2006076706A1

  公开（公告）日：2006-07-20

  [EN] The present invention provides novel cinnamide compounds of formula (I) useful as inhibitors of raf -protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and use thereof in the treatment of various cell proliferative diseases, wherein the rings B and C, G and L are as defined herein.
  [FR] L'invention concerne de nouveaux composés de cinnamide de formule (I) utiles en tant qu'inhibiteurs de Raf protéines kinases. L'invention concerne également des compositions pharmaceutiques comprenant ces composés et des méthodes d'utilisation des compositions susmentionnées pour traiter des maladies prolifératives cellulaires variées. Dans cette formule, les anneaux B et C, G¹et L¹ sont définis dans la description.
• Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors
  作者：Alexandra E. Gould、Ruth Adams、Sharmila Adhikari、Kathleen Aertgeerts、Roushan Afroze、Christopher Blackburn、Emily F. Calderwood、Ryan Chau、Jouhara Chouitar、Matthew O. Duffey、Dylan B. England、Cheryl Farrer、Nancy Forsyth、Khristofer Garcia、Jeffery Gaulin、Paul D. Greenspan、Ribo Guo、Sean J. Harrison、Shih-Chung Huang、Natalia Iartchouk、Dave Janowick、Mi-Sook Kim、Bheemashankar Kulkarni、Steven P. Langston、Jane X. Liu、Li-Ting Ma、Saurabh Menon、Hirotake Mizutani、Erin Paske、Christelle C. Renou、Mansoureh Rezaei、R. Scott Rowland、Michael D. Sintchak、Michael D. Smith、Stephen G. Stroud、Ming Tregay、Yuan Tian、Ole P. Veiby、Tricia J. Vos、Stepan Vyskocil、Juliet Williams、Tianlin Xu、Johnny J. Yang、Jason Yano、Hongbo Zeng、Dong Mei Zhang、Qin Zhang、Katherine M. Galvin

  DOI：10.1021/jm101479y

  日期：2011.3.24

  Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.
• Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
  申请人：Adams S. Ruth

  公开号：US20060160803A1

  公开（公告）日：2006-07-20

  The present invention provides novel cinnamide compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

  本发明提供了一种新型的肉桂酰胺化合物，可用作蛋白激酶的抑制剂。该发明还提供了包括该发明化合物的药物组合物，以及在治疗各种疾病中使用这些组合物的方法。